> China FDA wants drugmakers to prove equivalency testing of generic drugs as part of a broader effort to reduce applications for new generic approvals and focus on faster approvals for innovative drugs, according to a draft proposal put out for comment and cited by law firm Sidley Austin. The regulator is seeking comments on the draft proposals up to Aug. 15. Blog
> U.S.-based Minerva Biotechnologies and iPS Academia Japan signed an agreement allowing Minerva worldwide rights to use and commercialize the induced pluripotent stem (iPS) cells patent portfolio arising from the work of Nobel laureate Professor Shinya Yamanaka. Release
> The U.S. FDA imposed an import alert on some personal care products manufactured by Himalaya Drug Co. at Hyderabad, Bengaluru and Himachal Pradesh, the Business Standard newspaper reported. Report
> GlaxoSmithKline ($GSK) Pharmaceuticals India updated its annual report to note that its planned greenfield manufacturing facility at Bengaluru with a capacity of more than 9 billion tablets and capsules per year will be operational by 2017, The Hindu Business Line reported. Report
> India's Unichem Laboratories has voluntarily recalled one lot of hydrochlorothiazide tablets used to treat high blood pressure from the U.S. market due to the identification of another type of tablet in a bottle of the product, the Times of India said. Report
> Singapore-listed QT Vascular plans to set up a drug-coating development center in Singapore to boost research and development efforts in its Chocolate Touch drug-coated angioplasty balloon program, The Business Times reported. Report
> Australian researchers led by Professor Christoph Hagemeyer, head of the Vascular Biotechnology Laboratory at Baker IDI Heart and Diabetes Institute, have found a way to remove life-threatening blood clots using a drug-loaded nanocapsule coated with an antibody that targets activated platelets, Business Insider said. Report